Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising particulate celecoxib in an amount of about 10 mg to about 1000 mg in intimate mixture with one or more pharmaceutically acceptable excipients. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders.

Non-hygroscopic, azithromycin (9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin) dihydrate and a process therefor.

Non-hygroscopic, azithromycin (9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin) dihydrate and a process therefor.

72222-84 Disclosed are crystalline azithromycin (9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin) dihydrate and a process for producing the same. The crystalline dihydrate is non-hygroscopic and is easier to prepare and maintain the product in a form having a constant reproducible water content then hygroscopic monohydrate. The dihydrate is produced by crystallization from tetrahydrofuran and aliphatic hydrocarbon in the presence of a sufficient amount of water.

Prepn. of crystalline azithromycin dihydrate comprises crystallization from a mixt. of THF and C5-7 hydrocarbon in the presence of at least 2 mol. equivs. of H2O. Azithromycin is a broad spectrum antibacterial cpd. derived from erythromycin. The stable dehydrate cpd. is essentially non-hygroscopic under conditions of relative humidity conductive to formulation of azithromycin.